Updates and Considerations for the Multidisciplinary Management of Breast Cancer Through the COVID-19 Pandemic

Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC

Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer

SYN818 Shows Favorable Safety Profile in Locally Advanced or Metastatic Solid Tumors

Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer